Chinese pharmaceutical group WuXi AppTec has said it is lobbying hard in Washington against a proposed bill that threatens its business in the US, where it generates 65 per cent of its revenues.“The company has been actively working together with its advisers to set the record straight and advocate for changes to the proposed legislation,” Edward Hu, vice-chair and chief investment officer, said in an analysts’ call on Tuesday following the release of full-year results.
manbetx3.0 医药集团药明康德(WuXi AppTec)表示，其正在华盛顿努力游说，反对一项将威胁其美国业务的拟议法案。该公司65%的收入来自美国。
您已阅读15%（543字），剩余85%（2975字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。